13therapeutics, Inc.

13Therapeutics, Inc is a spin out from the Oregon Health and Science University (OHSU) and has exclusively licensed peptides on a world-wide basis. The company performs all in vitro testing in-house and subcontracts with OHSU and other academic instututions for animal model testing.  The company is privately funded and has received over $10 M in NIH peer reviewed grants, including multiple Phase I and Phase II SBIR grants.